Jedan od glavnih ciljeva Life4me+ — jeste da spreči nove slučajeve HIV-a i ostalih polno prenosivih infekcija, hepatitisa C i tuberkuloze.

Aplikacija pomaže da se uspostavi anonimna komunikacija između lekara i osoba koje žive sa HIV-om. Omogućava da lakše organizujete Vaš raspored upotrebe lekova i da postavite prikrivene i personalizovane podsetnike.

Sve vesti / Decembar 2018

Arhiviraj

✕

28 децембар 2018

6886

GlycA: A New Biomarker of Cardiovascular Disease Risk in People Living with HIV

GlycA: A New Biomarker of Cardiovascular Disease Risk in People Living with HIV

#GlycA levels — a particular biomarker for cardiovascular disease risk — showed higher rates among people living with HIV, and also correlated with other biomarkers for the activation of inflammation and indicators of subclinical coronary atherosclerosis, according to data ...

25 децембар 2018

6625

The combination of lamivudine/dolutegravir is effectiveness in the treatment of HIV-1

The combination of lamivudine/dolutegravir is effectiveness in the treatment of HIV-1

As follows from the results of a study recently published in the journal Lancet, lamivudine / doloutegravir combination therapy demonstrated satisfactory efficacy, safety, and tolerability in treating people with HIV-1.

24 децембар 2018

7061

In the United States will be able to use tenofovir for the treatment of hepatitis B in children

In the United States will be able to use tenofovir for the treatment of hepatitis B in children

The Food and Drug Administration (FDA) has supported Gilead, the manufacturer of the drug Viread (tenofovir disoproxil fumarate), in support of the drug. The regulator has approved the use of drugs for the treatment of hepatitis B among children from two years.

21 децембар 2018

5616

Scientists manage to destroy ex vivo "reservoirs" of HIV

Scientists manage to destroy ex vivo "reservoirs" of HIV

The current methods of treating HIV infection imply the need for patients to receive lifelong therapy, since even the most modern drugs are not yet able to eliminate the viral "reservoirs" that are hiding in immune cells. A group of researchers from the Pasteur Institute ...

18 децембар 2018

5545

HIV vaccine protects non-human primates from infection

HIV vaccine protects non-human primates from infection

The new study shows that rhesus macaque monkeys can be prompted to produce neutralizing antibodies against one strain of HIV that resembles the resilient viral form that most commonly infects people, called a Tier 2 virus. The research also provides the first-ever estimate ...

14 децембар 2018

5812

Michel Sidibe will leave UNAIDS in June 2019

Michel Sidibe will leave UNAIDS in June 2019

The head of the United Nations Program on HIV / AIDS (UNAIDS), Michel Sidibé, announced that he would resign early in June of the coming year. The resignation of the UNAIDS head has become known against the backdrop of a scandal that has flared up in the organization in ...

13 децембар 2018

6632

PEPFAR Program to Fight HIV/AIDS will be extended

PEPFAR Program to Fight HIV/AIDS will be extended

On Tuesday, 11 Dec., Washington was unanimously adopted by Congress and signed by US President Donald Trump to extend the country's largest program to combat HIV / AIDS PEPFAR.

11 децембар 2018

6887

Sixth case of HIV transmission to person taking PrEP

Sixth case of HIV transmission to person taking PrEP

In the United States, the sixth case of HIV transmission to a person with a high degree of adherence to pre-exposure prophylaxis (PrEP) has been reported. According to a report published this week in Lancet magazine, a 21-year-old Latin American from San Francisco test tested ...

7 децембар 2018

7057

European activists demanded that EPO withdraw Gilead's patent for sofosbuvir

European activists demanded that EPO withdraw Gilead's patent for sofosbuvir

Six nongovernmental organizations this week appealed the September decision of the European Patent Office (EPO) support a patent for the pharmaceutical company Gilead Sciences for a key drug for the treatment of hepatitis C sofosbuvir.

4 децембар 2018

7056

BHIVA: “Undeterminable workload - zero risk of HIV transmission”

BHIVA: “Undeterminable workload - zero risk of HIV transmission”

The British HIV Association (BHIVA) has called for the rejection of “misleading” statements about the “minimal” or “minor” risk of HIV transmission when it comes to undetectable viral load. The principle "undetectable = untransmittable" does not allow for inaccuracies in ...